Abstract
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease.
Original language | English |
---|---|
Article number | mdu123 |
Pages (from-to) | 1475-1484 |
Number of pages | 10 |
Journal | Annals of Oncology |
Volume | 25 |
Issue number | 8 |
Early online date | 25 Mar 2014 |
DOIs | |
Publication status | Published - 1 Aug 2014 |
Bibliographical note
All costs relating to the consensus conference were covered from the European Society for Medical Oncology central funds. There was no external funding of the event or manuscript production.Keywords
- Consensus
- Esmo
- Further lines
- Non-small-cell lung cancer